Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis genetically engineered expressing SARS-CoV-2 RBD
- Development stage
- Preclinical
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A **genetically engineered Bacillus subtilis** spore vaccine displays the *receptor binding domain* (RBD) of the SARS-CoV-2 spike protein on its surface, utilizing gene fusions (e.g., with spore coat proteins such as CotC, CotA, CotB, CotZ, or CotY) to present the antigen. This construct is designed for **oral administration**: B. subtilis spores are highly resistant to gastrointestinal conditions, enabling delivery of the antigen to the gut and induction of systemic immune responses, particularly neutralizing antibodies against SARS-CoV-2. Preclinical safety and immunogenicity were demonstrated in both mice and a human pilot study: three oral courses induced neutralizing antibody formation without significant adverse events. This technology is considered a candidate for an **oral COVID-19 vaccine** with potential benefits including stability, ease of modification and production, and suitability for challenging environments[1][3][5].
- Other names
- bacillus subtilis expressing SARS-CoV-2 RBDrecombinant bacillus subtilis SARS-CoV-2 vaccinerecombinant B. subtilis spores displaying RBD
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on bacillus subtilis genetically engineered expressing SARS-CoV-2 RBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis genetically engineered expressing SARS-CoV-2 RBD.